64 therapies, 38 evidence-based combinations. 5 guideline societies. 73 PMID-cited pivotal trials. The engine resolves them into one transparent, cited recommendation — in under 100 milliseconds.
Approved IBD therapies have nearly doubled in three years. Every new comparative study redraws the map — and every patient sits somewhere different on it.
Risankizumab, ustekinumab, vedolizumab, upadacitinib, guselkumab. Which ranks first here depends on phenotype, comorbidity and prior exposure.
ECCO, AGA, ACG, BSG, DGVS — each society, its own wording. Published comparative analyses rarely crown the same winner.
Elderly with CV risk and latent TB. Pregnant and escalating. The contraindication checklist grows with every new approval.
Five societies’ guidelines and 73 cited trials, scored into a single ranked list. Not a black box.
Every therapy is scored against the specific clinical profile — disease, severity, Montreal classification, comorbidities, prior failures — and returned as a transparent ranking.
UC or CD, severity, extent (E1–E3) or Montreal (A×L×B), prior failed therapies, comorbidities — TB, pregnancy, CV risk, renal function.
Active TB blocks biologics. Pregnancy blocks JAK inhibitors. Heart failure blocks anti-TNF. Before any ranking — no exceptions, no overrides.
Five societies' guidelines and 73 PMID-cited pivotal trials are scored for this exact profile — efficacy, safety, onset, durability, route.
Therapies come back ranked with transparent scores. Every line traces to the guideline paragraph or trial that produced it.
Three anonymized profiles from the validation set. Pick one — the engine gates, scores and ranks in real time.
The engine doesn't invent medicine. It reconciles what the field already knows — and proves the output holds up.
Where guidelines disagree, both positions surface — with the weighting applied, in the open.
Across 50,000 combinatorially generated scenarios, the engine matched the expected guideline pathway in 99.81% of runs.
50,000 validation scenarios, zero contraindicated recommendations surfaced. Gates run before ranking — every time.
A guideline-safe answer inside a 15-minute slot — citation ready for the chart.
Same evidence, same weighting, every clinician. Sequencing decisions you can defend in board review.
See exactly why #1 outranks #2. The scoring is the curriculum.
Early access is open to licensed gastroenterologists and IBD centers.